Dynavax Technologies News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.11.24	Dynavax To Buyback $100 Mln Of Shares (RTTNews)
29.10.24	Dynavax Adopts Poison Pill Or Limited-duration Shareholder Rights Plan (RTTNews)
14.05.24	Dynavax Receives FDA's CRL Regarding Four-Dose Heplisav-B Vaccine For Hemodialysis Patients (RTTNews)
30.04.24	Biotech Stocks Facing FDA Decision In May 2024 (RTTNews)
20.11.23	Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference (PR Newswire)
26.10.23	Dynavax to Report Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023 (PR Newswire)
19.10.23	Dynavax to Present at the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference (PR Newswire)
06.09.23	Dynavax to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
20.07.23	Dynavax to Report Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023 (PR Newswire)
30.05.23	Dynavax to Present at Upcoming Investor Conferences (PR Newswire)
08.05.23	Dynavax to Present at the JMP Securities Life Sciences Conference (PR Newswire)
18.04.23	Dynavax to Report First Quarter 2023 Financial Results and Host Conference Call on May 2, 2023 (PR Newswire)
01.03.23	Dynavax to Present at the Cowen 43rd Annual Health Care Conference (PR Newswire)
28.02.23	Dynavax Gets Great Britain Marketing Authorization For Hepatitis B Vaccine Heplisav B (RTTNews)
28.02.23	Dynavax Announces Great Britain Marketing Authorization for HEPLISAV B®, a Two-Dose Adult Hepatitis B Adjuvanted Vaccine (PR Newswire)
09.02.23	Dynavax to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023 (PR Newswire)
31.01.23	Dynavax Announces Uplisting to the Nasdaq Global Select Market (PR Newswire)
09.01.23	Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline Results (PR Newswire)
09.11.22	Dynavax to Present at Two Upcoming Investor Conferences (PR Newswire)
20.10.22	Dynavax to Report Third Quarter Financial Results and Host Conference Call on November 3, 2022 (PR Newswire)
14.10.22	Dynavax to Present at the H.C. Wainwright 3rd Annual Hepatitis B Virus Virtual Conference (PR Newswire)
12.09.22	Dynavax Announces First Participant Dosed in a Phase 2 Clinical Trial Evaluating an Adjuvanted Plague Vaccine (PR Newswire)
08.09.22	Dynavax to Present at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
21.07.22	Dynavax to Report Second Quarter Financial Results and Host Conference Call on August 4, 2022 (PR Newswire)
25.05.22	Dynavax to Present at the William Blair 42nd Annual Growth Stock Conference (PR Newswire)
16.05.22	Dynavax to Present at the H.C. Wainwright Global Investment Conference (PR Newswire)
13.05.22	Dynavax Rises 23%; Set To Join S&P SmallCap 600 (RTTNews)
13.05.22	Independence Realty Trust Set to Join S&P MidCap 400; Alpha and Omega Semiconductor & Dynavax Technologies to Join S&P SmallCap 600 (PR Newswire)
21.04.22	Dynavax to Report First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022 (PR Newswire)
05.04.22	Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
08.03.22	Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
03.03.22	Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
23.02.22	Dynavax to Present at the Cowen 42nd Annual Health Care Conference (PR Newswire)
16.02.22	Dynavax to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022 (PR Newswire)
02.02.22	Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
10.01.22	Dynavax Highlights 2022 Priorities and Announces Initiation of Phase 1 Clinical Trial for Its Shingles Vaccine Candidate (PR Newswire)
07.01.22	Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
05.01.22	Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference (PR Newswire)
28.12.21	COVID-19 Vaccine Developed by Biological E Using Dynavax's CpG 1018 Adjuvant Receives India DCGI Approval for Emergency Use (PR Newswire)
14.12.21	Elaine D. Sun Appointed to Dynavax Board of Directors (PR Newswire)
02.12.21	Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
18.11.21	Dynavax to Present at the 4th Annual Evercore Virtual ISI HealthCONx Conference (PR Newswire)
05.11.21	Pre-market Movers: RWLK, OTRK, EVAX, NRXP, PTON… (RTTNews)
02.11.21	Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
21.10.21	Scott Myers Appointed to Dynavax Board of Directors and Elected Board Chairman (PR Newswire)
21.10.21	Dynavax to Report Third Quarter 2021 Financial Results and Host Conference Call on November 4, 2021 (PR Newswire)
18.10.21	Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
18.10.21	Pre-market Movers: JCS, VALN, RVNC, HX, AVDL… (RTTNews)
18.10.21	COVID-19 Vaccine Developed by Valneva Using Dynavax's CpG 1018 Adjuvant Meets Both Co-Primary Endpoints in Phase 3 COV-COMPARE Trial (PR Newswire)
04.10.21	Dynavax and U.S. Department of Defense Announce Collaboration to Develop an Adjuvanted Plague Vaccine Using Dynavax's CpG 1018 Adjuvant (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	121.15	2.19 %	K V
Logitech Intl	72.20	1.66 %	K V
Lonza Grp	526.60	1.00 %	K V
Swiss Re	129.35	0.82 %	K V
UBS Group	28.35	0.18 %	K V
Givaudan	3’901.00	-0.81 %	K V
Swiss Life Hldg	725.40	-1.12 %	K V
Holcim	89.78	-1.12 %	K V
Novartis	91.93	-1.87 %	K V
Sonova Hldg	306.20	-1.89 %	K V

Nachrichten zu Dynavax Technologies Corp

Aktien Top/Flop

Meistgelesene Nachrichten